Publications by authors named "Xu He Zhang"
This study aimed to evaluate the efficacy and safety of the intravitreal injection of conbercept in the treatment of macular neovascularization (MNV) secondary to high myopia and to observe the application of optical coherence tomography angiography (OCTA) in the treatment follow-up. We reviewed the medical records of 20 patients (21 eyes) with MNV secondary to high myopia who were enrolled in the Department of Ophthalmology of the First Hospital of China Medical University between May 2018 and January 2020. Each patient received one or more intravitreal injections of conbercept (0.
View Article and Find Full Text PDFArticle Synopsis
- * Out of 2,197 patients identified (110 pediatric and 2,087 adult), pediatric patients showed a higher likelihood of having localized cancer, less regional node involvement, and underwent more extensive surgery.
- * Survival rates were significantly better for pediatric patients, with their cancer-specific survival (CSS) and overall survival (OS) markedly higher compared to adults, even when accounting for more advanced stages.
Objective: The present study was designed to better characterize the clinicopathological features and prognosis in patients aged ≥65 years with pulmonary large cell neuroendocrine carcinoma (LCNEC).
Methods: Eligible patients with pulmonary LCNEC were retrieved from the Surveillance, Epidemiology, and End Results database between January 2004 and December 2013. The primary endpoints included cancer-specific survival (CSS) and overall survival (OS).
Article Synopsis
- * A systematic review and meta-analysis of three studies with 2650 patients found no significant differences in adverse events or skeletal-related events between administering zoledronic acid every 12 weeks and every 4 weeks.
- * The 12-week dosing interval may even lead to lower instances of serious side effects like osteonecrosis of the jaw and kidney dysfunction, suggesting it could be a viable treatment option.